Skip to search formSkip to main contentSkip to account menu

ISIS 2302

Known as: ISIS-2302 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

alicaforsen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Two phase 3 studies of alicalorsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease
Highly Cited
2002
Highly Cited
2002
Dose ranging pharmacokinetic trial of high‐dose alicaforsen (intercellular adhesion molecule‐1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease
Background and aims : To evaluate the safety, pharmacokinetics and clinical efficacy of the intercellular adhesion molecule‐1… 
2002
2002
INFLAMMATORY BOWEL DISEASE Double blind , placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide , alicaforsen ( ISIS 2302…
Background and aims: To evaluate the safety and efficacy of the intercellular adhesion molecule 1 (ICAM-1) antisense… 
2000
2000
Anti-sense ICAM-1 (ISIS-2302) for subcutaneous treatment of chronic active Crohn's disease (CACD): Lack of efficacy in a prospective, double-blind, multicenter randomized trial
2000
2000
Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
The pharmacokinetics of subcutaneous (s.c.) administration of a phosphorothioate oligodeoxynucleotide (PS-ODN) was evaluated in… 
1999
1999
ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1.
ISIS 2302 is a 20 base phosphorothioate oligodeoxynucleotide (ODN) that inhibits intercellular adhesion molecule 1 (ICAM-1… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)